<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of pulmonary eosinophilia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of pulmonary eosinophilia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of pulmonary eosinophilia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy D Klion, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce S Bochner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 10, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Eosinophilic lung diseases are a heterogeneous group of disorders that share the feature of abnormally increased numbers of eosinophils within the pulmonary airways and parenchyma [<a href="#rid1">1-3</a>]. </p><p>The major causes of pulmonary eosinophilia will be reviewed here (<a class="graphic graphic_table graphicRef76875" href="/z/d/graphic/76875.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef64886" href="/z/d/graphic/64886.html" rel="external">table 2</a>). Pleural fluid eosinophilia and the differential diagnosis of blood eosinophilia and eosinophilia of other tissues are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6704.html" rel="external">"Pleural fluid eosinophilia"</a> and  <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a> and  <a class="medical medical_review" href="/z/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia", section on 'Disorders with eosinophilic involvement of specific organs'</a> and  <a class="medical medical_review" href="/z/d/html/120281.html" rel="external">"Infectious causes of peripheral eosinophilia"</a>.)</p><p class="headingAnchor" id="H734893870"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>The defining characteristics of pulmonary eosinophilia include the following [<a href="#rid4">4-6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral blood eosinophilia (absolute eosinophil count ≥500 eosinophils/microL) with abnormalities on pulmonary imaging studies</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased eosinophils in bronchoalveolar lavage (BAL) fluid (eg, &gt;10 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung tissue eosinophilia demonstrated in transbronchial or open lung biopsies</p><p></p><p>Peripheral blood eosinophils are, by no means, uniformly increased in all types of eosinophilic lung diseases [<a href="#rid7">7,8</a>], and conventional chest radiographs may fail to detect lung parenchymal disease [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H2478256515"><span class="h1">CAUSES AND CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2"><span class="h2">Helminth infections</span><span class="headingEndMark"> — </span>Helminth infections elicit several pathophysiologically distinct forms of pulmonary eosinophilia depending on the behavior of the organisms in the lung and the associated host immune response [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia", section on 'Parasites and other infections'</a> and  <a class="medical medical_review" href="/z/d/html/120281.html" rel="external">"Infectious causes of peripheral eosinophilia"</a>.)</p><p class="headingAnchor" id="H3"><span class="h3">Transpulmonary passage of helminth larvae (Löffler syndrome)</span><span class="headingEndMark"> — </span>Three types of helminths, <em>Ascaris (A. lumbricoides</em>, <em>A. suum</em>), hookworms (<em>Ancylostoma duodenale</em>, <em>Necator americanus</em>), and <em>Strongyloides stercoralis</em>, have life cycles in which infecting larvae reach the lungs via the bloodstream, penetrate into alveoli, mature, and ascend the airways before descending the alimentary tract into the small bowel [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis", section on 'Epidemiology'</a>.)</p><p>The syndrome of transient pulmonary radiographic opacities and peripheral blood eosinophilia was originally described by Löffler; <em>Ascaris</em> infection acquired from the use of contaminated human night-soil as fertilizer was determined to be the cause [<a href="#rid11">11</a>]. Subsequent investigations have confirmed that <em>Ascaris</em> is the most common cause of Löffler syndrome worldwide (<a class="graphic graphic_figure graphicRef79015" href="/z/d/graphic/79015.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis"</a>.) </p><p>Migrating larvae of hookworms and <em>Strongyloides</em> are less likely to elicit symptoms or pulmonary eosinophilia [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/5721.html" rel="external">"Hookworm infection"</a> and  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis"</a>.)</p><p>Symptomatic patients most often complain of an irritating, nonproductive cough and burning substernal discomfort that is aggravated by coughing or deep breathing. Dyspnea, wheezing, fever, and blood-tinged sputum containing eosinophil-derived Charcot-Leyden crystals may also be present (<a class="graphic graphic_picture graphicRef71997" href="/z/d/graphic/71997.html" rel="external">picture 1</a>). </p><p>The chest radiograph may show round or oval opacities ranging in size from several millimeters to several centimeters in both lung fields; these lesions are more likely to be present when blood eosinophilia exceeds 10 percent. The opacities are migratory and may become confluent in perihilar areas but usually clear spontaneously and completely after several weeks. </p><p>Definitive diagnosis of ascariasis at the time of pulmonary symptoms requires detection of <em>Ascaris</em>,<em> Strongyloides</em>, or hookworm larvae in the respiratory secretions. Stool examinations are generally negative at the time of pulmonary symptoms and thus not useful in the diagnosis of Löffler syndrome. </p><p class="headingAnchor" id="H4"><span class="h3">Pulmonary parenchymal invasion</span><span class="headingEndMark"> — </span>Several helminths can directly invade the pulmonary parenchyma and produce long-lasting pulmonary manifestations rather than briefly passing through the lungs en route to the gastrointestinal (GI) tract as described above. These latter organisms include <em>Paragonimus</em> lung flukes and cestodes (ie, <em>Echinococcus</em>, <em>Taenia solium</em>) [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/5679.html" rel="external">"Paragonimiasis", section on 'Pulmonary paragonimiasis'</a> and  <a class="medical medical_review" href="/z/d/html/5669.html" rel="external">"Echinococcosis: Clinical manifestations and diagnosis", section on 'Lung involvement'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paragonimiasis</strong> – <em>Paragonimus</em> lung flukes can invade the lungs and produce pleural effusions or eosinophil-enriched inflammatory infiltrates [<a href="#rid10">10</a>]. Endemic areas are listed in the table (<a class="graphic graphic_table graphicRef97880" href="/z/d/graphic/97880.html" rel="external">table 3</a>). Symptoms can include recurrent hemoptysis and chocolate-colored sputum, which is composed of a mixture of blood, inflammatory cells, and <em>Paragonimus</em> eggs (<a class="graphic graphic_figure graphicRef56115" href="/z/d/graphic/56115.html" rel="external">figure 2</a>). Blood eosinophilia tends to be prominent in the early stages of disease but minimal with established disease. In contrast, the immunoblot or enzyme-linked immunosorbent assay (ELISA) for antibodies to <em>Paragonimus</em> is more useful later in infection. </p><p></p><p class="bulletIndent1"><em>Paragonimus</em> lung lesions are typically nodular with surrounding areas of ground glass (<a class="graphic graphic_diagnosticimage graphicRef59176" href="/z/d/graphic/59176.html" rel="external">image 1</a>). The lesions are usually peripheral and are common in the mid- and lower lung zones, in contrast to tuberculosis, which is in the differential diagnosis of hemoptysis but more likely to cause apical cavities. The diagnosis of paragonimiasis is typically made by finding eggs in the sputum or bronchoalveolar lavage fluid (<a class="graphic graphic_picture graphicRef63741" href="/z/d/graphic/63741.html" rel="external">picture 2</a>) or by a positive ELISA. (See  <a class="medical medical_review" href="/z/d/html/5679.html" rel="external">"Paragonimiasis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echinococcosis and cysticercosis</strong> – Leakage or rupture of pulmonary cysts in echinococcosis (<em>Echinococcus granulosus, Echinococcus multilocularis</em>) or cysticercosis (<em>Taenia solium</em>) can also cause pulmonary eosinophilia. Antibodies to echinococcus (<a class="graphic graphic_figure graphicRef86230" href="/z/d/graphic/86230.html" rel="external">figure 3</a>) can be detected by enzyme-linked immunosorbent assay (ELISA), while the enzyme-linked immunoelectrotransfer blot assay (EITB) may be useful in the diagnosis of cysticercosis when neuroimaging studies are not diagnostic (<a class="graphic graphic_table graphicRef78175" href="/z/d/graphic/78175.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/z/d/html/5668.html" rel="external">"Epidemiology and control of echinococcosis", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/5669.html" rel="external">"Echinococcosis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5693.html" rel="external">"Cysticercosis: Epidemiology, transmission, and prevention", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/5678.html" rel="external">"Cysticercosis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Heavy hematogenous seeding</span><span class="headingEndMark"> — </span>Heavy hematogenous seeding of helminth larvae or eggs can lead to lung deposition and an eosinophilic pulmonary response. This type of hematogenous spread is not essential for the parasite life cycle, in contrast to the "normal" transpulmonary migration noted above. In the case of strongyloidiasis, prior treatment with glucocorticoids may be a risk factor. Pulmonary symptoms such as cough, wheezing, and dyspnea may result, and blood eosinophilia is common. </p><p>The syndrome can arise in several settings, including the following [<a href="#rid10">10,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ascarids and hookworms</strong> – Ascarids (eg, <em>Toxocara canis</em>, <em>Toxocara cati</em>, Ascaris suum), which typically cause visceral larva migrans, and hookworms, which cause cutaneous larva migrans, can also spread hematogenously to the lungs when large numbers of larvae are released into the blood stream (<a class="graphic graphic_figure graphicRef79015" href="/z/d/graphic/79015.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef61675" href="/z/d/graphic/61675.html" rel="external">figure 4</a>) [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis", section on 'Early phase: Pulmonary manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/5716.html" rel="external">"Toxocariasis: Visceral and ocular larva migrans"</a> and  <a class="medical medical_review" href="/z/d/html/5718.html" rel="external">"Hookworm-related cutaneous larva migrans", section on 'Pulmonary disease'</a>.)</p><p></p><p class="bulletIndent1">The majority of individuals with ascariasis live in Asia, Africa, and South America. Toxocariasis occurs worldwide. (See  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/5716.html" rel="external">"Toxocariasis: Visceral and ocular larva migrans", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trichinellosis</strong> – While serious pulmonary disease due to <em>Trichinella</em> infection is rare, pulmonary involvement can occur when large numbers of <em>Trichinella</em> larvae are spread hematogenously. Trichinellosis occurs worldwide, although the specific species and prevalences vary (<a class="graphic graphic_figure graphicRef83128" href="/z/d/graphic/83128.html" rel="external">figure 5</a>). Trichinellosis should be considered in patients with periorbital edema, myositis, and eosinophilia. </p><p></p><p class="bulletIndent1">The diagnosis is typically based on the history, clinical presentation, and peripheral blood eosinophilia. Serologic testing can be used to confirm the diagnosis, but does not become positive for two to eight weeks after infection. (See  <a class="medical medical_review" href="/z/d/html/5719.html" rel="external">"Trichinellosis", section on 'Pulmonary disease'</a> and  <a class="medical medical_review" href="/z/d/html/5719.html" rel="external">"Trichinellosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schistosomiasis</strong> – Schistosomiasis is associated with pulmonary eosinophilia in two settings. Schistosomal adult worms can spread to the lungs via collateral vessels following anthelminthic therapy, particularly in patients with portal hypertension. In addition, eosinophilic pneumonia may occur in the early phase (three to six weeks) after infection with schistosomes; patients may experience cough and shortness of breath, and chest computed tomographic (CT) scanning may detect multiple small nodules and, less commonly, ground glass opacities [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1">The diagnosis is typically based on the history, clinical presentation, and peripheral blood eosinophilia since serologic testing and stool examination for ova are typically negative at the time of acute symptoms. Areas of the world with endemic schistosomiasis are shown in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwwwnc.cdc.gov%2Ftravel%2Fyellowbook%2F2020%2Ftravel-related-infectious-diseases%2Fschistosomiasis&amp;token=PF11zPfctG4AyYlX1Mj4iFh3drcmkYtp3Eke%2ByJCWHNL%2BCbCu15qLSLOC3XFU91O63bAdpp57rxTua6DugKHOX0390WETV9ngpyoPmbAMfAnc3odvPZMYzzt2vraaOIv&amp;TOPIC_ID=5715" target="_blank">map of the distribution of schistosomiasis</a>. (See  <a class="medical medical_review" href="/z/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>Strongyloides</em></strong> – Hyperinfection and dissemination of <em>Strongyloides</em> larvae may produce invasion of a number of organs (including the lungs) separate from the transpulmonary passage, which is required for the helminthic life cycle (<a class="graphic graphic_figure graphicRef87284" href="/z/d/graphic/87284.html" rel="external">figure 6</a>). Hyperinfection is typically associated with immunosuppression, but can occur in the absence of demonstrable immunosuppression. Typical manifestations include dyspnea, wheezing, cough, and fever. The chest radiograph usually shows diffuse ground glass opacities. The diagnosis can be made by the presence of eggs or larvae in bronchoalveolar lavage (BAL) fluid. Serologic testing by ELISA for IgG antibodies to <em>Strongyloides</em> is often positive, while stool examination is often negative. (See  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis"</a> and  <a class="medical medical_review" href="/z/d/html/5717.html" rel="external">"Schistosomiasis: Epidemiology and clinical manifestations", section on 'Pulmonary complications'</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Tropical pulmonary eosinophilia</span><span class="headingEndMark"> — </span>Tropical pulmonary eosinophilia results from a distinct immune response to the bloodborne microfilarial stages of the lymphatic filariae, <em>Wuchereria bancrofti</em> and, less commonly, <em>Brugia malayi</em> [<a href="#rid16">16-18</a>]. These organisms are spread by mosquito bites. The typical symptoms are cough, breathlessness, wheezing, fatigue, and fever. </p><p>Pulmonary function tests may show a mixed restrictive and obstructive abnormality with a reduction in diffusion capacity [<a href="#rid18">18</a>]. Chest radiographs typically show diffuse opacities (<a class="graphic graphic_diagnosticimage graphicRef75859" href="/z/d/graphic/75859.html" rel="external">image 2</a>), although approximately 20 percent of affected patients have a normal chest radiograph [<a href="#rid18">18,19</a>]. CT scans are more sensitive than chest radiography; typical findings include reticular and small nodular opacities, bronchiectasis, air trapping, calcification, and mediastinal adenopathy [<a href="#rid18">18,19</a>].</p><p>The diagnosis is based on the finding of typical respiratory symptoms and radiographic abnormalities in patients with a history of residence or travel in a filaria-endemic region (eg, Indian subcontinent, South East Asia, Africa, South America) with associated dramatic peripheral eosinophilia (frequently &gt;3000/microL), markedly elevated serum IgE (frequently &gt;1000 units/mL), and serology showing markedly elevated antifilarial IgG antibodies. (See  <a class="medical medical_review" href="/z/d/html/5711.html" rel="external">"Tropical pulmonary eosinophilia"</a>.)</p><p>An identical but nonfilarial syndrome of tropical pulmonary eosinophilia of uncertain etiology has also been recognized [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Fungal and mycobacterial infections</span><span class="headingEndMark"> — </span>Primary coccidioidal infection can be associated with eosinophilic pneumonia [<a href="#rid21">21,22</a>]. Symptomatic infection due to <em>Coccidioides</em> most frequently manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a>.)</p><p>Most patients who are suspected to have coccidioidomycosis are evaluated with serologic testing, although antibody testing may be negative early in the course of disease; enzyme-linked immunoassays for specific IgM and IgG are probably the most sensitive screening tests. Differentiation from idiopathic eosinophilic pneumonia can be difficult because organisms may be absent from cultures and open lung biopsy specimens [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/2420.html" rel="external">"Coccidioidomycosis: Laboratory diagnosis and screening", section on 'Detection of anticoccidioidal antibodies'</a>.) </p><p>Pulmonary and peripheral blood eosinophilia have been reported in disseminated cryptococcal infection [<a href="#rid24">24-26</a>]. (See  <a class="medical medical_review" href="/z/d/html/2421.html" rel="external">"Cryptococcus neoformans infection outside the central nervous system"</a>.)</p><p>Pulmonary mucormycosis (<em>Cunninghamella bertholletiae</em>) has been associated with eosinophilia in peripheral blood and bronchoalveolar lavage in a case report [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p>Pulmonary eosinophilia rarely complicates pulmonary tuberculosis [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H73866602"><span class="h2">Viral infection</span><span class="headingEndMark"> — </span>Acute eosinophilic pneumonia has been described in SARS-CoV-2 infection [<a href="#rid29">29,30</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Medications and toxins</span><span class="headingEndMark"> — </span>Pulmonary eosinophilia has been reported following the ingestion or inhalation of a variety of medications and toxins. The importance of identifying drug or toxin-induced pulmonary eosinophilia cannot be overemphasized as many cases will resolve with withdrawal of the offending agent. </p><p>The various clinical presentations of drug-induced pulmonary eosinophilia include asymptomatic pulmonary infiltration with eosinophils, chronic cough with or without dyspnea and fever, acute eosinophilic pneumonia, and drug reaction with eosinophilia and systemic symptoms (DRESS) [<a href="#rid31">31,32</a>]. DRESS should be suspected when the patient has a skin eruption, fever, facial edema, enlarged lymph nodes, and a history of initiation of a culprit medication two to six weeks prior to disease onset (<a class="graphic graphic_table graphicRef86760" href="/z/d/graphic/86760.html" rel="external">table 5</a>). The diagnosis is based on the combination of clinical features, cutaneous and systemic findings, and laboratory testing, as described separately. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common culprit medications</strong> – Nonsteroidal anti-inflammatory drugs (NSAIDs), antimicrobials (<a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>, <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>), <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a>, and <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> are the most common classes of drugs associated with pulmonary eosinophilia [<a href="#rid31">31,32</a>]. Other implicated agents include anticonvulsants, antidepressants, angiotensin converting enzyme inhibitors, beta blockers, <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> and other sulfa-containing compounds, radiographic contrast media, L-tryptophan, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, and <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Implicated toxin exposures</strong> – A number of toxin exposures have been associated with pulmonary eosinophilia including [<a href="#rid34">34-42</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aluminum silicate and particulate metals [<a href="#rid34">34</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Sulfite-exposed grape workers [<a href="#rid35">35</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Scorpion stings [<a href="#rid36">36,43</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Inhalation of heroin, crack cocaine, or marijuana [<a href="#rid37">37,44,45</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Inhalation of organic chemicals during rubber manufacture [<a href="#rid38">38</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Inhalation of dust or smoke, as in exposure to fireworks, firefighting, tobacco smoking [<a href="#rid39">39-41,46</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Abuse of 1,1,1-trichloroethane (Scotchgard) [<a href="#rid42">42</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outbreaks</strong> – Rare outbreaks of pulmonary eosinophilia have been described. The largest of these, the "toxic oil syndrome," affected &gt;20,000 people in Spain in 1981, and was associated with ingestion of rapeseed oil contaminated with aniline derivatives [<a href="#rid47">47</a>]. A similar outbreak, "eosinophilia-myalgia syndrome" occurred in 1989, in association with L-tryptophan ingestion. Although the predominant complaints were neuromuscular, &gt;50 percent of the affected individuals had cough or dyspnea and 17 percent had pulmonary involvement [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Idiopathic acute eosinophilic pneumonia</span><span class="headingEndMark"> — </span>Idiopathic acute eosinophilic pneumonia (AEP) is a type of eosinophilic pneumonia associated with the rapid development of acute respiratory failure in a previously healthy patient. AEP is often associated with recent initiation or resumption of cigarette smoking, vaping [<a href="#rid49">49</a>], and less commonly with heavy inhalational exposure to smoke, fine sand, or dust. Clusters of AEP have occurred in military troops [<a href="#rid46">46</a>] and firefighters [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia", section on 'Etiology'</a> and  <a class="medical medical_review" href="/z/d/html/122671.html" rel="external">"E-cigarette or vaping product use-associated lung injury (EVALI)"</a>.)</p><p>Most patients present with an acute febrile illness of less than seven days' duration, characterized by a nonproductive cough, dyspnea, and a variety of nonspecific radiographic changes (<a class="graphic graphic_diagnosticimage graphicRef50572 graphicRef71567" href="/z/d/graphic/50572.html" rel="external">image 3A-B</a>). Peripheral eosinophilia is rare at presentation, but may develop during the course of the disease. Hypoxemic respiratory insufficiency and diffuse pulmonary opacities on imaging are frequently identified at presentation and often require mechanical ventilation. (See  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia", section on 'Clinical features'</a>.)</p><p>The diagnosis is based on the clinical presentation, imaging findings, flexible bronchoscopy with bronchoalveolar lavage that reveals ≥25 percent eosinophils, and the absence of infection or other known precipitant (<a class="graphic graphic_table graphicRef76875" href="/z/d/graphic/76875.html" rel="external">table 1</a>). Lung biopsy is reserved for situations when the diagnosis is uncertain. Histopathologic findings include diffuse alveolar damage, hyaline membranes, and marked numbers of interstitial and lesser numbers of alveolar eosinophils (<a class="graphic graphic_picture graphicRef74556 graphicRef58648" href="/z/d/graphic/74556.html" rel="external">picture 3A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia", section on 'Diagnosis'</a>.)  </p><p class="headingAnchor" id="H10"><span class="h2">Chronic eosinophilic pneumonia</span><span class="headingEndMark"> — </span>Chronic eosinophilic pneumonia (CEP) is an idiopathic disorder characterized by an abnormal accumulation of eosinophils in the lung [<a href="#rid7">7</a>]. CEP occurs predominantly in women and nonsmokers; cases have been reported following radiation therapy for breast cancer [<a href="#rid50">50-52</a>]. The syndrome often presents as a subacute illness with a constellation of symptoms including cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases. Peripheral blood eosinophilia is common, but may be absent in 10 to 20 percent of patients [<a href="#rid7">7,50</a>]. (See  <a class="medical medical_review" href="/z/d/html/4360.html" rel="external">"Chronic eosinophilic pneumonia"</a>.)</p><p>The chest radiographic finding of bilateral peripheral or pleural-based infiltrates described as the "photographic negative" of pulmonary edema is virtually pathognomonic for the disease (<a class="graphic graphic_diagnosticimage graphicRef86465" href="/z/d/graphic/86465.html" rel="external">image 4</a> and <a class="graphic graphic_picture graphicRef86464" href="/z/d/graphic/86464.html" rel="external">picture 4</a>), but is found in fewer than one-third of cases [<a href="#rid7">7</a>]. Pleural effusions [<a href="#rid53">53</a>] and cavitation [<a href="#rid54">54</a>] are infrequent findings. BAL eosinophilia ≥25 percent is suggestive of CEP. Nodular bronchial mucosal lesions that reveal necrotizing eosinophilic inflammation have been reported in association with CEP [<a href="#rid55">55</a>]. Histopathology of lung biopsy specimens reveals interstitial and alveolar eosinophils and histiocytes, including multinucleated giant cells (<a class="graphic graphic_picture graphicRef77554" href="/z/d/graphic/77554.html" rel="external">picture 5</a>). Fibrosis is minimal, and organizing pneumonia is a commonly associated finding [<a href="#rid7">7</a>]. </p><p>The diagnosis is based upon the combination of a subacute presentation, characteristic radiographic findings, and peripheral blood or BAL eosinophilia and the absence of infection or drug-induced pulmonary eosinophilia (<a class="graphic graphic_table graphicRef76875" href="/z/d/graphic/76875.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/4360.html" rel="external">"Chronic eosinophilic pneumonia", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Eosinophilic granulomatosis with polyangiitis</span><span class="headingEndMark"> — </span>Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) is a vasculitic disorder often characterized by sinusitis, asthma, and prominent peripheral blood eosinophilia [<a href="#rid56">56</a>]. In addition to the lungs, the skin and the cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved. (See  <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>.)</p><p>Peripheral blood eosinophilia over 1500 cells/microL (or greater than 10 percent of the total leukocyte count) is part of the diagnostic criteria for EGPA, but much higher levels (&gt;5000 eosinophils/microL) are common. Antineutrophil cytoplasmic antibodies (ANCA) are found in less than 50 percent of EGPA patients with pulmonary involvement and, when present, are most often of the myeloperoxidase (MPO) perinuclear staining pattern. (See  <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Laboratory tests'</a>.)</p><p>Chest radiograph abnormalities in patients with EGPA are quite diverse, but most commonly consist of transient and patchy opacities without lobar or segmental distribution (<a class="graphic graphic_diagnosticimage graphicRef71677 graphicRef59884 graphicRef73909" href="/z/d/graphic/71677.html" rel="external">image 5A-C</a>). Pathognomonic findings on lung biopsy include eosinophilic infiltrates, an eosinophilic vasculitis (especially of the small arteries and veins), interstitial and perivascular necrotizing granulomas, and areas of necrosis (<a class="graphic graphic_picture graphicRef50143 graphicRef57180 graphicRef82366" href="/z/d/graphic/50143.html" rel="external">picture 6A-C</a>). However, tissues from patients presenting with new onset EGPA may not exhibit all of the classic pathologic features of this syndrome, but rather may resemble the eosinophilic infiltration without vasculitis typical of CEP or hypereosinophilic syndrome [<a href="#rid57">57</a>]. In some patients with EGPA, a diagnosis of CEP precedes the onset of the vasculitic syndrome.</p><p>The diagnosis of EGPA is typically suspected based on the clinical findings (ie, eosinophilia ≥1500/microL, asthma, paranasal sinus disease). A positive MPO-ANCA is strong evidence in favor of the diagnosis. Definitive diagnosis typically requires a tissue biopsy from the most accessible site of disease, prior to the initiation of systemic glucocorticoid therapy. The diagnostic criteria for EGPA are described separately. (See  <a class="medical medical_review" href="/z/d/html/4347.html" rel="external">"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Diagnostic criteria'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Allergic bronchopulmonary aspergillosis/mycosis</span><span class="headingEndMark"> — </span>Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction that occurs when airways become colonized by <em>Aspergillus</em> [<a href="#rid58">58</a>]. Repeated episodes of bronchial obstruction, inflammation, and mucoid impaction can lead to bronchiectasis, fibrosis, and respiratory compromise. Immunologic responses elicited by <em>Aspergillus fumigatus</em> in the airways are responsible for this syndrome (<a class="graphic graphic_table graphicRef104812" href="/z/d/graphic/104812.html" rel="external">table 6</a>) (see  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a>). </p><p>Although most of the published data relate to ABPA, a similar syndrome, allergic bronchopulmonary mycosis (ABPM) has been reported in response to other fungal pathogens, including <em>Alternaria</em>, <em>Penicillium</em>, <em>Curvularia</em>, and <em>Schizophyllum</em> sp [<a href="#rid59">59,60</a>].</p><p>The clinical picture of ABPA/ABPM is dominated by underlying asthma (or cystic fibrosis), complicated by recurrent episodes of bronchial obstruction, fever, malaise, expectoration of brownish mucous plugs, peripheral blood eosinophilia, and hemoptysis. Wheezing is not always evident, and some patients present with asymptomatic pulmonary consolidation. High resolution computed tomography (HRCT) scan of the thorax may show widespread proximal cylindrical bronchiectasis with upper lobe predominance and bronchial wall thickening. While central bronchiectasis with normal tapering of distal bronchi is considered a classic manifestation of ABPA/ABPM, this finding is neither sensitive nor specific for the disorder (<a class="graphic graphic_diagnosticimage graphicRef64077" href="/z/d/graphic/64077.html" rel="external">image 6</a>). (See  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis", section on 'Imaging'</a>.)</p><p>Histologic findings in patients with ABPA/ABPM include asthmatic bronchiolitis, eosinophilic pneumonia, bronchocentric granulomatosis, and mucoid impaction of bronchi [<a href="#rid61">61</a>]. On occasion, bronchocentric granulomatosis presents with pulmonary eosinophilia in the absence of endobronchial fungi [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/z/d/html/4322.html" rel="external">"Bronchocentric granulomatosis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Miscellaneous causes</span><span class="headingEndMark"> — </span>A number of other conditions are less commonly causes of pulmonary eosinophilia. Examples include:</p><p class="headingAnchor" id="H14"><span class="h3">Hypereosinophilic syndromes</span><span class="headingEndMark"> — </span>The hypereosinophilic syndromes (HES), some of known and some of idiopathic etiology, are associated with marked peripheral eosinophilia and eosinophilic involvement of diverse organs such as the heart, GI tract, lungs, brain, and kidneys [<a href="#rid63">63,64</a>]. Hypereosinophilia is defined as a blood eosinophil count &gt;1500 cells/microL; a hypereosinophilic syndrome is defined by the association of hypereosinophilia with eosinophil-mediated organ damage and/or dysfunction. Pulmonary symptoms (eg, cough and breathlessness) are seen in up to 65 percent of patients [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Other idiopathic lung diseases</span><span class="headingEndMark"> — </span>Lung diseases, such as idiopathic pulmonary fibrosis, sarcoidosis, and hypersensitivity pneumonitis, can be associated with modest degrees of eosinophilia in the BAL fluid and on biopsy [<a href="#rid66">66</a>]. Less commonly, pulmonary eosinophilia occurs in association with cryptogenic organizing pneumonia, rheumatoid arthritis, Sjögren's disease, radiation-induced lung injury, and graft-versus-host disease (<a class="graphic graphic_table graphicRef64886" href="/z/d/graphic/64886.html" rel="external">table 2</a>) [<a href="#rid4">4,67,68</a>]. Pulmonary eosinophilia can also be associated with lung allograft rejection [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease", section on 'Eosinophilic BAL'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Neoplasms</span><span class="headingEndMark"> — </span>Peripheral and/or localized pulmonary eosinophilic infiltration occasionally occurs in conjunction with undifferentiated lung carcinomas or lung metastases of cervical tumors; squamous carcinomas of the vagina, penis, skin, or nasopharynx; adenocarcinomas of the stomach, large bowel or uterine body; or transitional cell bladder carcinoma [<a href="#rid70">70</a>]. Pulmonary eosinophilia may also occur when lymphoma, acute eosinophilic leukemia, or the Sézary syndrome involves the lung [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Acute eosinophilic leukemia'</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">DIAGNOSTIC APPROACH</span><span class="headingEndMark"> — </span>The diagnostic approach to patients with suspected pulmonary eosinophilia must be dictated by the specific clinical findings and the setting in which they occur [<a href="#rid72">72</a>]. Every patient should undergo a thorough history and physical examination.</p><p class="headingAnchor" id="H18"><span class="h2">History and physical examination</span></p><p>When obtaining the history, attention should be paid to the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Medication and chemical exposures, including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and antibiotics, as well as exposures to dust, smoke (eg, firefighting, tobacco smoke, vaping), or chemicals. (See <a class="local">'Medications and toxins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Travel and immigration histories, including residence in or travel to regions endemic for <em>Coccidioides</em> and varied parasites (more frequently encountered outside of the United States, although <em>Ascaris</em> and <em>Strongyloides</em> are found in rural areas in the southeastern US).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of ingestion of poorly cooked pork, wild boar, or other wild animal meats associated with complaints of muscle pain, tenderness, swelling, and weakness. (See <a class="local">'Heavy hematogenous seeding'</a> above and  <a class="medical medical_review" href="/z/d/html/5719.html" rel="external">"Trichinellosis", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory history and findings, including antecedent or concomitant asthma, as found in allergic bronchopulmonary aspergillosis/mycosis (ABPA/ABPM), eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss), and sometimes chronic eosinophilic pneumonia (CEP) or helminthic etiologies. Duration of any antecedent symptoms should be considered. Acute eosinophilic pneumonia (AEP) is characteristically abrupt in onset, whereas CEP develops insidiously over months. Asthma in EGPA may begin years before the development of vasculitic lung involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of symptoms or signs of extrapulmonary organ involvement, since these may be indicative of systemic diseases, including EGPA, hypereosinophilic syndromes, and neoplasms. (See  <a class="medical medical_review" href="/z/d/html/100544.html" rel="external">"Eosinophil biology and causes of eosinophilia", section on 'Disorders with eosinophilic involvement of specific organs'</a>.)</p><p></p><p>A key component of the physical examination is looking for cutaneous lesions that might indicate a certain diagnosis or provide an opportunity for a less invasive biopsy site. Stigmata of rheumatic diseases (eg, muscle weakness, joint swelling, or erythema) should be sought. </p><p><br/>Lung examination is nonspecific, although wheezes would be more consistent with EGPA, CEP, or ABPA, while crackles would be more likely with drug-induced pulmonary eosinophilia, AEP, or less commonly CEP.</p><p class="headingAnchor" id="H19"><span class="h2">Blood eosinophilia</span><span class="headingEndMark"> — </span>The presence of an elevated peripheral blood absolute eosinophil count (AEC; ie, ≥500 cells/microL) helps to support the diagnosis of a number of the entities discussed above. However, the magnitude of blood eosinophilia is <strong>not</strong> a reliable means to distinguish between the possible etiologies of pulmonary eosinophilia, and the absence of blood eosinophilia does not exclude the majority of these conditions.</p><p>A bacterial pneumonia is typically associated with an eosinopenic response, in part due to heightened endogenous glucocorticoid production. Thus, even mild or moderate blood eosinophilia in a patient with an acute or subacute pulmonary disease should prompt evaluation for one of the disorders considered above.</p><p>Some of the conditions that have pulmonary eosinophilia are not associated with peripheral blood eosinophilia, such as acute eosinophilic pneumonia and sometimes chronic eosinophilic pneumonia. Additionally, concomitant or recent glucocorticoid therapy can suppress blood eosinophilia. </p><p class="headingAnchor" id="H1054896452"><span class="h2">Serologic and other laboratory tests</span><span class="headingEndMark"> — </span>Serologic testing can be helpful in the diagnosis of some pulmonary eosinophilic disorders. However, some test results may not be rapidly available, and patients with a recent infection may not have developed antibodies, thus limiting the utility of serologic testing in the evaluation of an acutely ill patient.</p><p>Selection of serologic tests is guided by the likely exposures (based on geographic residence and travel) and disease patterns. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Strongyloidiasis – Enzyme-linked immunoassay (ELISA) for antibodies to <em>Strongyloides</em>. It is important to identify patients with strongyloidiasis, as treatment with systemic glucocorticoids in a patient with undiagnosed infection can cause disseminated, and potentially fatal, bacterial infection. The sensitivity and specificity of serologic testing is variable, as described separately. (See <a class="local">'Heavy hematogenous seeding'</a> above and  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ascariasis – Serologic testing not clinically useful. (See  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trichinellosis – ELISA or other serologic test. (See  <a class="medical medical_review" href="/z/d/html/5719.html" rel="external">"Trichinellosis", section on 'Serologic tests'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Filariasis – Testing for anti-filarial antibodies. (See <a class="local">'Tropical pulmonary eosinophilia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paragonimiasis, echinococcosis, cysticercosis – ELISA or immunoblot for specific antibodies. (See <a class="local">'Pulmonary parenchymal invasion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coccidioidomycosis – Enzyme-linked immunoassays for IgM and IgG specific for <em>Coccidioides</em> antibodies. (See <a class="local">'Fungal and mycobacterial infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EGPA (Churg-Strauss) – Antineutrophil cytoplasmic antibodies (ANCA). (See <a class="local">'Eosinophilic granulomatosis with polyangiitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergic bronchopulmonary aspergillosis – Total serum IgE, <em>Aspergillus</em>-specific IgE and IgG. (See <a class="local">'Allergic bronchopulmonary aspergillosis/mycosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serologic studies for systemic rheumatic diseases are obtained based on the finding of suggestive features on the history and physical examination.</p><p></p><p>Sputum examination for ova and parasites can be useful in patients with a suggestive clinical presentation and travel or residence in areas endemic for helminths, such as <em>Paragonimus</em>, <em>Ascaris</em>, <em>Strongyloides</em>, or hookworms. (See <a class="local">'Helminth infections'</a> above.)</p><p class="headingAnchor" id="H20"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Radiographic imaging of the chest, especially by high resolution computed tomography (HRCT), can provide valuable findings early in the investigation of the patient. The ability of HRCT scans to differentiate among the causes of pulmonary eosinophilia has been evaluated in a series of 111 patients with eosinophilic lung disease [<a href="#rid73">73</a>]. The three diseases that could be diagnosed with greatest certainty by HRCT were CEP, ABPA, and AEP.</p><p class="bulletIndent1"><span class="glyph">●</span>Characteristic CT findings of CEP include: bilateral consolidative opacities and areas of ground-glass attenuation, involving predominantly the peripheral regions of the middle or upper lung zones [<a href="#rid50">50,73-75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Common CT findings of ABPA consist of bronchiectasis, mucous plugging, bronchial wall thickening, atelectasis, consolidation, areas of ground-glass attenuation, and upper and central lung predominance [<a href="#rid73">73</a>]. The first three of these findings are the most indicative of ABPA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CT findings in AEP include ground-glass attenuation, consolidation, poorly defined nodules, interlobular septal thickening, and pleural effusions (<a class="graphic graphic_diagnosticimage graphicRef101077" href="/z/d/graphic/101077.html" rel="external">image 7</a>). The triad of interlobular septal thickening, bronchovascular bundle thickening, and pleural effusions are most suggestive of this diagnosis [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CT findings in EGPA [<a href="#rid76">76</a>], drug-induced pulmonary eosinophilia [<a href="#rid77">77</a>], hypereosinophilic syndrome (HES), and simple pulmonary eosinophilia are varied and diverse. Thus, a radiologic diagnosis of these entities is rarely possible [<a href="#rid73">73</a>].</p><p></p><p>With all of the eosinophilic lung diseases, radiographic findings need to be combined with clinical and other features to guide the approach to diagnosis [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Flexible bronchoscopy</span><span class="headingEndMark"> — </span>Unless the history and noninvasive evaluation identify a provocative agent (eg, helminth infection, medication) as a likely cause of an eosinophilic lung disease, flexible bronchoscopy with bronchoalveolar lavage (BAL) is usually necessary. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchoalveolar lavage</strong> – BAL fluid should be evaluated for the total and differential leukocyte counts. Since mild to moderate airway eosinophilia can occur in a number of common conditions, including asthma, a cut-off of ≥25 percent for the diagnosis of AEP or CEP has been suggested, although the specificities of these criteria have not been evaluated prospectively (<a class="graphic graphic_table graphicRef64886" href="/z/d/graphic/64886.html" rel="external">table 2</a>) [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1">If the patient has been in an area endemic for coccidioidomycosis or has clinical and radiographic findings suggestive of ABPA, fungal cultures should be obtained (and the laboratory alerted to the possibility of coccidioidomycosis). Examination of the BAL fluid for ova and larvae is appropriate for patients with residence or travel to endemic areas for the various helminths. Bacterial and mycobacterial cultures should also be performed. (See <a class="local">'Fungal and mycobacterial infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transbronchial biopsy</strong> – In general, transbronchial biopsy is less likely to secure a confident diagnosis than surgical lung biopsy. However, when EGPA (Churg-Strauss) is suspected, a definitive diagnosis can sometimes be made on a transbronchial biopsy, thus avoiding a more invasive lung biopsy procedure. (See <a class="local">'Eosinophilic granulomatosis with polyangiitis'</a> above.)</p><p></p><p class="headingAnchor" id="H168839340"><span class="h2">Lung biopsy</span><span class="headingEndMark"> — </span>For causes of pulmonary eosinophilia other than infection, medication, or toxin, it is important to establish and document the nature of the disease. While EGPA, AEP, CEP, and often HES will respond to glucocorticoid therapy, establishing a firm pathologic diagnosis upfront is prudent given the side effects of long-term glucocorticoid treatment and the options for second-line therapy in glucocorticoid-refractory disease. Moreover, since EGPA has the potential to involve and damage other organs, documenting this vasculitis has important implications for the future management of the patient. </p><p>As with the general evaluation of interstitial lung disease a surgical approach is typically preferred over a transbronchial biopsy due to the small size of transbronchial specimens. Video-assisted thoracoscopic surgery (VATS) can substitute for a thoracotomy to provide tissue. (See  <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Role of lung biopsy'</a> and  <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease"</a>.)</p><p class="headingAnchor" id="H3285067958"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of pulmonary eosinophilia depends on the underlying cause. An overview is provided in the following sections.</p><p class="headingAnchor" id="H2333171670"><span class="h2">Infectious causes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transpulmonary passage of helminth larvae (Löffler syndrome)</strong> - Specific treatment of Löffler syndrome is generally not necessary, although anthelminthic therapy for intestinal infection after resolution of respiratory symptoms may be appropriate. (See  <a class="medical medical_review" href="/z/d/html/5721.html" rel="external">"Hookworm infection", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/487.html" rel="external">"Anthelminthic therapies"</a> and  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis", section on 'Early phase: Pulmonary manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenchymal invasion by </strong><strong><em>Paragonimus</em></strong><strong>, </strong><strong><em>Taenia solium</em></strong><strong>, </strong><strong><em>Echinococcus</em></strong> – Treatment of parenchymal invasion by <em>Paragonimus</em> or tapeworms requires antihelminthic therapy selected based on the specific infection and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5679.html" rel="external">"Paragonimiasis", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/5671.html" rel="external">"Echinococcosis: Treatment"</a> and  <a class="medical medical_review" href="/z/d/html/5685.html" rel="external">"Tapeworm infections", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heavy hematogenous seeding of helminth larvae or eggs</strong> – Treatment of heavy hematogenous seeding is based on reduction or eradication of the parasite with specific therapy depending on the organism; occasionally systemic glucocorticoids are used to stem the inflammatory response. </p><p class="bulletIndent1">(See  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/5719.html" rel="external">"Trichinellosis", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/5705.html" rel="external">"Schistosomiasis: Treatment and prevention", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis", section on 'Severe disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tropical pulmonary eosinophilia</strong> – Initial treatment usually consists of oral <a class="drug drug_general" data-topicid="112050" href="/z/d/drug information/112050.html" rel="external">diethylcarbamazine</a> (DEC); occasionally, systemic glucocorticoids are used to treat accompanying wheezing and bronchoconstriction. Treatment is described separately. (See  <a class="medical medical_review" href="/z/d/html/5711.html" rel="external">"Tropical pulmonary eosinophilia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coccidioidomycosis</strong> – Use of antifungal agents for pulmonary coccidioidomycosis depends on the severity of disease risk of dissemination or complications, as described separately. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection", section on 'Management'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucormycosis</strong> – Mucormycosis (zygomycosis) requires specific antifungal therapy and sometimes surgical debridement. (See  <a class="medical medical_review" href="/z/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculosis</strong> – Treatment of tuberculosis is described separately. (See  <a class="medical medical_review" href="/z/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a>.)</p><p></p><p class="headingAnchor" id="H2513714738"><span class="h2">Noninfectious causes</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications and toxins</strong> – Pulmonary eosinophilia due to drugs or toxins is largely treated with cessation of the implicated agent. For patients with severe respiratory impairment or drug reaction with eosinophilia and systemic symptoms (DRESS), a course of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> is usually indicated, as noted in the following examples: (See  <a class="medical medical_review" href="/z/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/4371.html" rel="external">"Nitrofurantoin-induced pulmonary injury", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/4315.html" rel="external">"Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic acute eosinophilic pneumonia</strong> – Acute eosinophilic pneumonia (AEP) is usually treated with systemic glucocorticoids due to the degree of respiratory impairment. (See  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic eosinophilic pneumonia</strong> – Chronic eosinophilic pneumonia (CEP) is typically treated with systemic glucocorticoids, as fewer than 10 percent of patients spontaneously recover or improve. Case reports suggest that biologic agents targeting eosinophils (eg, anti-interleukin [IL]-5 agents) may be useful in preventing relapse in CEP, but further study is needed [<a href="#rid79">79-81</a>]. (See  <a class="medical medical_review" href="/z/d/html/4360.html" rel="external">"Chronic eosinophilic pneumonia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophilic granulomatosis with polyangiitis</strong> – Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) requires prompt treatment guided by the vasculitis disease activity, comorbidities, and response to initial therapy with systemic glucocorticoids. Additional therapy (eg, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, anti-interleukin-5 antibodies, IgE antibodies) may be needed. (See  <a class="medical medical_review" href="/z/d/html/4346.html" rel="external">"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypereosinophilic syndromes</strong> – Some of the hypereosinophilic syndromes require immediate treatment (<a class="graphic graphic_algorithm graphicRef103933" href="/z/d/graphic/103933.html" rel="external">algorithm 1</a>), some require treatment but not urgently, and others, such as asymptomatic familial eosinophilia and hypereosinophilia of unknown significance (asymptomatic), can be safely monitored. The indications for treatment and choice of agents are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2210.html" rel="external">"Hypereosinophilic syndromes: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic bronchopulmonary aspergillosis</strong> – Treatment of allergic bronchopulmonary aspergillosis (ABPA) aims to control episodes of acute inflammation and to limit progressive lung injury. The roles of systemic glucocorticoids and antifungal agents vary with the disease activity. Antieosinophil biologics may have a role in the treatment of eosinophilic pneumonia with fungal sensitization, including ABPA [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/z/d/html/104431.html" rel="external">"Treatment of allergic bronchopulmonary aspergillosis", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Pulmonary eosinophilia of undetermined cause</span><span class="headingEndMark"> — </span>Although most of the varied etiologies of pulmonary eosinophilia (with the exception of strongyloidiasis) will improve on glucocorticoids, the empiric use of systemic glucocorticoids for the treatment of pulmonary eosinophilia remains controversial in many settings. In general, systemic glucocorticoid administration is reserved for patients with acute respiratory distress and hypoxemia due to idiopathic acute eosinophilic pneumonia (AEP) or a medication or toxin-elicited acute pulmonary eosinophilia. It should be noted, though, that AEP can resolve spontaneously without glucocorticoid therapy [<a href="#rid83">83</a>]. Glucocorticoids may be indicated during anthelminthic therapy for patients with dyspnea due to bronchoconstriction.</p><p class="bulletIndent1">For other chronic or potentially systemic causes of pulmonary eosinophilia, we suggest NOT giving empiric glucocorticoids, at least until a diagnostic biopsy has been performed. Glucocorticoids given prior to a biopsy may suppress tissue eosinophilia and alter the histopathology, obscuring the chance to obtain a definitive diagnosis. </p><p></p><p>Following a biopsy, glucocorticoids may be given as clinically indicated pending biopsy results, as long as <em>Strongyloides</em> is not suspected. Patients with gastrointestinal <em>Strongyloides</em> infection can develop massive dissemination of filariform larvae to the lungs and other organs, called hyperinfection syndrome, with even a short course of systemic glucocorticoid therapy. For patients with possible <em>Strongyloides</em> infection, empiric treatment for <em>Strongyloides</em> with <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> without waiting for the results of laboratory testing is prudent prior to systemic glucocorticoid administration. (See  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis"</a>.)</p><p class="headingAnchor" id="H25079319"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The defining characteristics of pulmonary eosinophilia include peripheral blood eosinophilia (ie, ≥500 cells/microL) with radiographic evidence of pulmonary parenchymal disease; histopathologic evidence of lung tissue eosinophilia in a transbronchial or open lung biopsy specimen; and increased eosinophils in bronchoalveolar lavage fluid (eg, &gt;10 percent). (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A number of helminth infections are associated with pulmonary eosinophilia. The following patterns have been described:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transpulmonary passage of <em>Ascaris</em>, hookworms, and <em>Strongyloides</em>, also known as Löffler syndrome. (See <a class="local">'Transpulmonary passage of helminth larvae (Löffler syndrome)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary parenchymal invasion by <em>Paragonimus</em> lung flukes or cestodes (eg, <em>Taenia solium</em>). (See <a class="local">'Pulmonary parenchymal invasion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heavy hematogenous seeding of helminthic larvae or eggs (eg, hookworms, <em>Ascaris</em>, <em>Trichinella</em>, <em>Schistosoma</em>, <em>Strongyloides</em>). (See <a class="local">'Heavy hematogenous seeding'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tropical pulmonary eosinophilia results from a distinct immune response to the bloodborne microfilaria (eg, <em>Wuchereria bancrofti</em>, <em>Brugia malayi</em>). (See <a class="local">'Tropical pulmonary eosinophilia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonhelminthic infections, such as Coccidioidomycosis and, less commonly, <em>Mycobacterium tuberculosis</em>, can be associated with pulmonary eosinophilia. Eosinophilic pneumonia has also been reported in the setting of COVID-19. (See <a class="local">'Fungal and mycobacterial infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary eosinophilia can follow the inhalation or ingestion of a variety of toxins (eg, tobacco smoke, rubber manufacture) and medications (eg, nonsteroidal anti-inflammatory drugs [NSAIDs], <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, anticonvulsants, angiotensin converting enzyme inhibitors]. A listing of medications associated with pulmonary eosinophilia can be found at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pneumotox.com%2Fdrug%2Findex%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAebUs0tWBJH2E4P6NjJKXt7lfaz85Ary5D81ipOGXzyNa&amp;TOPIC_ID=5715" target="_blank">Pneumotox</a>. (See <a class="local">'Medications and toxins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The classic presentation of idiopathic acute eosinophilic pneumonia (AEP) is the rapid onset of acute respiratory failure in a previously healthy patient. The diagnosis is based on the clinical presentation, diffuse radiographic opacities, and bronchoalveolar lavage with ≥25 percent eosinophils, and the absence of infection or other known precipitant (<a class="graphic graphic_table graphicRef76875" href="/z/d/graphic/76875.html" rel="external">table 1</a>). (See <a class="local">'Idiopathic acute eosinophilic pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In chronic eosinophilic pneumonia (CEP), peripheral blood eosinophilia is common, but can be absent in 10 to 20 percent. Bilateral peripheral or pleural-based opacities are a classic finding on chest radiograph, but not always present. Bronchoalveolar lavage (BAL) eosinophilia ≥25 percent (often ≥40 percent) further supports CEP. (See <a class="local">'Chronic eosinophilic pneumonia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) is a vasculitic disorder characterized by sinusitis, asthma, and prominent peripheral blood eosinophilia. Antineutrophil cytoplasmic antibodies (ANCA) are found in less than 50 percent of EGPA patients with pulmonary involvement. For patients with a negative ANCA, the diagnosis may require a tissue biopsy from the most accessible site of disease. (See <a class="local">'Eosinophilic granulomatosis with polyangiitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergic bronchopulmonary aspergillosis/mycosis (ABPA/ABPM) typically develops in patients with asthma, but can also complicate cystic fibrosis. The diagnosis is based upon several clinical, radiographic, and immunologic criteria that are described separately (<a class="graphic graphic_table graphicRef104812" href="/z/d/graphic/104812.html" rel="external">table 6</a>). (See <a class="local">'Allergic bronchopulmonary aspergillosis/mycosis'</a> above and  <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary eosinophilia can be a feature of hypereosinophilic syndromes (HES), defined as an absolute eosinophil count &gt;1500 cells/microL with evidence of end organ eosinophilic manifestations. A number of systemic diseases that are not usually associated with eosinophilia can have a modest degree of eosinophilic infiltration in the lung (eg, idiopathic pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia, systemic rheumatic diseases, malignancy). (See <a class="local">'Miscellaneous causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnostic approach to patients with pulmonary eosinophilia is dictated by the specific clinical findings and the setting in which they occur. The history, physical examination, radiographic, and laboratory findings are used to formulate a differential diagnosis and determine the need for invasive diagnostic testing. (See <a class="local">'Diagnostic approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The management of pulmonary eosinophilia depends on the underlying cause. The various helminth infections are typically treated with anthelminthic agents, depending on the specific organism and phase in the lifecycle. Noninfectious processes, such as AEP, CEP, and EGPA, are treated with systemic glucocorticoids and sometimes additional immunosuppressive or anti-eosinophil agents. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with pulmonary eosinophilia of undetermined cause, we suggest NOT giving empiric glucocorticoids, at least until a diagnostic biopsy has been performed. Glucocorticoids given prior to a biopsy may suppress tissue eosinophilia and alter the histopathology, obscuring the chance to obtain a definitive diagnosis. (See <a class="local">'Pulmonary eosinophilia of undetermined cause'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Akuthota P, Weller PF. Eosinophilic pneumonias. Clin Microbiol Rev 2012; 25:649.</a></li><li><a class="nounderline abstract_t">Khemasuwan D, Farver CF, Mehta AC. Parasites of the air passages. Chest 2014; 145:883.</a></li><li><a class="nounderline abstract_t">Bernheim A, McLoud T. A Review of Clinical and Imaging Findings in Eosinophilic Lung Diseases. AJR Am J Roentgenol 2017; 208:1002.</a></li><li><a class="nounderline abstract_t">Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994; 150:1423.</a></li><li><a class="nounderline abstract_t">Bain GA, Flower CD. Pulmonary eosinophilia. Eur J Radiol 1996; 23:3.</a></li><li><a class="nounderline abstract_t">Umeki S. Reevaluation of eosinophilic pneumonia and its diagnostic criteria. Arch Intern Med 1992; 152:1913.</a></li><li><a class="nounderline abstract_t">Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore) 1988; 67:154.</a></li><li><a class="nounderline abstract_t">Hayakawa H, Sato A, Toyoshima M, et al. A clinical study of idiopathic eosinophilic pneumonia. Chest 1994; 105:1462.</a></li><li><a class="nounderline abstract_t">Dejaegher P, Derveaux L, Dubois P, Demedts M. Eosinophilic pneumonia without radiographic pulmonary infiltrates. Chest 1983; 84:637.</a></li><li class="breakAll">Wilson ME, Weller PF. Eosinophilia. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 2nd ed, Guerrant RL, Walker DH, Weller PF (Eds), Elsevier, Philadelphia 2006. p.1478.</li><li><a class="nounderline abstract_t">LOFFLER W. Transient lung infiltrations with blood eosinophilia. Int Arch Allergy Appl Immunol 1956; 8:54.</a></li><li><a class="nounderline abstract_t">Singh P, Saggar K, Kalia V, et al. Thoracic imaging findings in a case of disseminated cysticercosis. Postgrad Med J 2011; 87:158.</a></li><li><a class="nounderline abstract_t">Roig J, Romeu J, Riera C, et al. Acute eosinophilic pneumonia due to toxocariasis with bronchoalveolar lavage findings. Chest 1992; 102:294.</a></li><li><a class="nounderline abstract_t">Inoue K, Inoue Y, Arai T, et al. Chronic eosinophilic pneumonia due to visceral larva migrans. Intern Med 2002; 41:478.</a></li><li><a class="nounderline abstract_t">Schwartz E, Rozenman J, Perelman M. Pulmonary manifestations of early schistosome infection among nonimmune travelers. Am J Med 2000; 109:718.</a></li><li><a class="nounderline abstract_t">Boggild AK, Keystone JS, Kain KC. Tropical pulmonary eosinophilia: a case series in a setting of nonendemicity. Clin Infect Dis 2004; 39:1123.</a></li><li><a class="nounderline abstract_t">Ottesen EA, Nutman TB. Tropical pulmonary eosinophilia. Annu Rev Med 1992; 43:417.</a></li><li><a class="nounderline abstract_t">Mullerpattan JB, Udwadia ZF, Udwadia FE. Tropical pulmonary eosinophilia--a review. Indian J Med Res 2013; 138:295.</a></li><li><a class="nounderline abstract_t">Sandhu M, Mukhopadhyay S, Sharma SK. Tropical pulmonary eosinophilia: a comparative evaluation of plain chest radiography and computed tomography. Australas Radiol 1996; 40:32.</a></li><li><a class="nounderline abstract_t">Rocha A, Dreyer G, Poindexter RW, Ottesen EA. Syndrome resembling tropical pulmonary eosinophilia but of non-filarial aetiology: serological findings with filarial antigens. Trans R Soc Trop Med Hyg 1995; 89:573.</a></li><li><a class="nounderline abstract_t">Fohlman J, Sjölin J, Bennich H, et al. Coccidioidomycosis as imported atypical pneumonia in Sweden. Scand J Infect Dis 2000; 32:440.</a></li><li><a class="nounderline abstract_t">Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol 2007; 45:26.</a></li><li><a class="nounderline abstract_t">Lombard CM, Tazelaar HD, Krasne DL. Pulmonary eosinophilia in coccidioidal infections. Chest 1987; 91:734.</a></li><li><a class="nounderline abstract_t">Yokoyama T, Kadowaki M, Yoshida M, et al. Disseminated Cryptococcosis with Marked Eosinophilia in a Postpartum Woman. Intern Med 2018; 57:135.</a></li><li><a class="nounderline abstract_t">Yamaguchi H, Komase Y, Ikehara M, et al. Disseminated cryptococcal infection with eosinophilia in a healthy person. J Infect Chemother 2008; 14:319.</a></li><li><a class="nounderline abstract_t">Bassetti M, Mikulska M, Nicco E, Viscoli C. Pulmonary cryptococcosis with severe eosinophilia in an immunocompetent patient. J Chemother 2010; 22:366.</a></li><li><a class="nounderline abstract_t">Hirano T, Yamada M, Sato K, et al. Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia. BMC Pulm Med 2017; 17:76.</a></li><li><a class="nounderline abstract_t">Vijayan VK, Reetha AM, Jawahar MS, et al. Pulmonary eosinophilia in pulmonary tuberculosis. Chest 1992; 101:1708.</a></li><li><a class="nounderline abstract_t">Descalzo V, Salvador F, Sansano I, et al. Acute Eosinophilic Pneumonia Associated With SARS-CoV-2 Infection. Arch Bronconeumol 2021; 57 Suppl 2:50.</a></li><li><a class="nounderline abstract_t">Murao K, Saito A, Kuronuma K, et al. Acute eosinophilic pneumonia accompanied with COVID-19: a case report. Respirol Case Rep 2020; 8:e00683.</a></li><li><a class="nounderline abstract_t">Taweesedt PT, Nordstrom CW, Stoeckel J, Dumic I. Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review. Biomed Res Int 2019; 2019:7863815.</a></li><li><a class="nounderline abstract_t">Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: A review of 196 case reports. Medicine (Baltimore) 2018; 97:e9688.</a></li><li class="breakAll">Camus P. Pneumotox: The Drug-Induced Respiratory Disease Website/Application. https://www.pneumotox.com (Accessed on November 08, 2021).</li><li><a class="nounderline abstract_t">Schwarz YA, Kivity S, Fischbein A, et al. Eosinophilic lung reaction to aluminium and hard metal. Chest 1994; 105:1261.</a></li><li><a class="nounderline abstract_t">Marguerie C, Drouet M. [Occupational eosinophilic lung in a grape grower: role of sulfites]. Allerg Immunol (Paris) 1995; 27:163.</a></li><li><a class="nounderline abstract_t">Shah PK, Lakhotia M, Chittora M, et al. Pulmonary infiltration with blood eosinophilia after scorpion sting. Chest 1989; 95:691.</a></li><li><a class="nounderline abstract_t">Nadeem S, Nasir N, Israel RH. Löffler's syndrome secondary to crack cocaine. Chest 1994; 105:1599.</a></li><li><a class="nounderline abstract_t">Bascom R, Fisher JF, Thomas RJ, et al. Eosinophilia, respiratory symptoms and pulmonary infiltrates in rubber workers. Chest 1988; 93:154.</a></li><li><a class="nounderline abstract_t">Rom WN, Weiden M, Garcia R, et al. Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust. Am J Respir Crit Care Med 2002; 166:797.</a></li><li><a class="nounderline abstract_t">Hirai K, Yamazaki Y, Okada K, et al. Acute eosinophilic pneumonia associated with smoke from fireworks. Intern Med 2000; 39:401.</a></li><li><a class="nounderline abstract_t">Shintani H, Fujimura M, Yasui M, et al. Acute eosinophilic pneumonia caused by cigarette smoking. Intern Med 2000; 39:66.</a></li><li><a class="nounderline abstract_t">Kelly KJ, Ruffing R. Acute eosinophilic pneumonia following intentional inhalation of Scotchguard. Ann Allergy 1993; 71:358.</a></li><li><a class="nounderline abstract_t">Adi-Bessalem S, Mendil A, Hammoudi-Triki D, Laraba-Djebari F. Lung immunoreactivity and airway inflammation: their assessment after scorpion envenomation. Inflammation 2012; 35:501.</a></li><li><a class="nounderline abstract_t">Tsapas A, Paletas K, Vlachaki E, et al. Eosinophilic pneumonia associated with heroin inhalation: a case report. Wien Klin Wochenschr 2008; 120:178.</a></li><li><a class="nounderline abstract_t">Liebling PD, Siu S. A novel cause of eosinophilic pneumonia: recreational marijuana exposure. J Bronchology Interv Pulmonol 2013; 20:183.</a></li><li><a class="nounderline abstract_t">Shorr AF, Scoville SL, Cersovsky SB, et al. Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. JAMA 2004; 292:2997.</a></li><li><a class="nounderline abstract_t">Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L. Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients. Medicine (Baltimore) 1993; 72:285.</a></li><li><a class="nounderline abstract_t">Swygert LA, Maes EF, Sewell LE, et al. Eosinophilia-myalgia syndrome. Results of national surveillance. JAMA 1990; 264:1698.</a></li><li><a class="nounderline abstract_t">Kligerman SJ, Kay FU, Raptis CA, et al. CT Findings and Patterns of e-Cigarette or Vaping Product Use-Associated Lung Injury: A Multicenter Cohort of 160 Cases. Chest 2021; 160:1492.</a></li><li><a class="nounderline abstract_t">Marchand E, Reynaud-Gaubert M, Lauque D, et al. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 1998; 77:299.</a></li><li><a class="nounderline abstract_t">Cottin V, Frognier R, Monnot H, et al. Chronic eosinophilic pneumonia after radiation therapy for breast cancer. Eur Respir J 2004; 23:9.</a></li><li><a class="nounderline abstract_t">Chaaban S, Salloum V. Chronic eosinophilic pneumonia in a breast cancer patient post-radiation therapy: a case report. Respir Care 2014; 59:e81.</a></li><li><a class="nounderline abstract_t">Samman YS, Wali SO, Abdelaal MA, et al. Chronic eosinophilic pneumonia presenting with recurrent massive bilateral pleural effusion : case report. Chest 2001; 119:968.</a></li><li><a class="nounderline abstract_t">Laufs U, Schneider C, Wassermann K, Erdmann E. Chronic eosinophilic pneumonia with atypical radiographic presentation. Respiration 1998; 65:323.</a></li><li><a class="nounderline abstract_t">Toyoshima M, Suda T, Chida K. Tracheobronchial involvement in chronic eosinophilic pneumonia. Am J Respir Crit Care Med 2012; 186:1057.</a></li><li><a class="nounderline abstract_t">Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.</a></li><li><a class="nounderline abstract_t">Weller PF, Plaut M, Taggart V, Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108:175.</a></li><li><a class="nounderline abstract_t">Gibson PG. Allergic bronchopulmonary aspergillosis. Semin Respir Crit Care Med 2006; 27:185.</a></li><li><a class="nounderline abstract_t">Deepak D, Singh Rajput M, Sharma B, Chowdhary A. Allergic Bronchopulmonary Mycosis due to fungi other than Aspergillus. Eur Ann Allergy Clin Immunol 2019; 51:75.</a></li><li><a class="nounderline abstract_t">Chowdhary A, Agarwal K, Kathuria S, et al. Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview. Crit Rev Microbiol 2014; 40:30.</a></li><li><a class="nounderline abstract_t">Logan PM, Müller NL. High-resolution computed tomography and pathologic findings in pulmonary aspergillosis: a pictorial essay. Can Assoc Radiol J 1996; 47:444.</a></li><li><a class="nounderline abstract_t">Katzenstein AL, Liebow AA, Friedman PJ. Bronchocentric granulomatosis, mucoid impaction, and hypersensitivity reactions to fungi. Am Rev Respir Dis 1975; 111:497.</a></li><li><a class="nounderline abstract_t">Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.</a></li><li><a class="nounderline abstract_t">Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124:1319.</a></li><li><a class="nounderline abstract_t">Zimmermann N, Wikenheiser-Brokamp KA. Hypereosinophilic syndrome in the differential diagnosis of pulmonary infiltrates with eosinophilia. Ann Allergy Asthma Immunol 2018; 121:179.</a></li><li><a class="nounderline abstract_t">Allen JN, Davis WB, Pacht ER. Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils. Am Rev Respir Dis 1990; 142:642.</a></li><li><a class="nounderline abstract_t">Yousem SA. Eosinophilic pneumonia-like areas in idiopathic usual interstitial pneumonia. Mod Pathol 2000; 13:1280.</a></li><li><a class="nounderline abstract_t">Norman D, Piecyk M, Roberts DH. Eosinophilic pneumonia as an initial manifestation of rheumatoid arthritis. Chest 2004; 126:993.</a></li><li><a class="nounderline abstract_t">Mogayzel PJ Jr, Yang SC, Wise BV, Colombani PM. Eosinophilic infiltrates in a pulmonary allograft: a case and review of the literature. J Heart Lung Transplant 2001; 20:692.</a></li><li><a class="nounderline abstract_t">Horie S, Okubo Y, Suzuki J, Isobe M. An emaciated man with eosinophilic pneumonia. Lancet 1996; 348:166.</a></li><li><a class="nounderline abstract_t">Jin JJ, Butterfield JH, Weiler CR. Hematologic Malignancies Identified in Patients with Hypereosinophilia and Hypereosinophilic Syndromes. J Allergy Clin Immunol Pract 2015; 3:920.</a></li><li><a class="nounderline abstract_t">Rosenberg CE, Khoury P. Approach to Eosinophilia Presenting With Pulmonary Symptoms. Chest 2021; 159:507.</a></li><li><a class="nounderline abstract_t">Johkoh T, Müller NL, Akira M, et al. Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients. Radiology 2000; 216:773.</a></li><li><a class="nounderline abstract_t">Mayo JR, Müller NL, Road J, et al. Chronic eosinophilic pneumonia: CT findings in six cases. AJR Am J Roentgenol 1989; 153:727.</a></li><li><a class="nounderline abstract_t">Ebara H, Ikezoe J, Johkoh T, et al. Chronic eosinophilic pneumonia: evolution of chest radiograms and CT features. J Comput Assist Tomogr 1994; 18:737.</a></li><li><a class="nounderline abstract_t">Silva CI, Müller NL, Fujimoto K, et al. Churg-Strauss syndrome: high resolution CT and pathologic findings. J Thorac Imaging 2005; 20:74.</a></li><li><a class="nounderline abstract_t">Erasmus JJ, McAdams HP, Rossi SE. High-resolution CT of drug-induced lung disease. Radiol Clin North Am 2002; 40:61.</a></li><li><a class="nounderline abstract_t">Cottin V, Cordier JF. Eosinophilic pneumonias. Allergy 2005; 60:841.</a></li><li><a class="nounderline abstract_t">Brenard E, Pilette C, Dahlqvist C, et al. Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia. Lung 2020; 198:355.</a></li><li><a class="nounderline abstract_t">To M, Kono Y, Yamawaki S, et al. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab. J Allergy Clin Immunol Pract 2018; 6:1746.</a></li><li><a class="nounderline abstract_t">Ricketti PA, Ricketti AJ. Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab. Ann Allergy Asthma Immunol 2021; 126:726.</a></li><li><a class="nounderline abstract_t">Dhariwal J, Hearn AP, Kavanagh JE, et al. Real-World Effectiveness of Anti-IL-5/5R Therapy in Severe Atopic Eosinophilic Asthma with Fungal Sensitization. J Allergy Clin Immunol Pract 2021; 9:2315.</a></li><li><a class="nounderline abstract_t">Philit F, Etienne-Mastroïanni B, Parrot A, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002; 166:1235.</a></li></ol></div><div id="topicVersionRevision">Topic 5715 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23034324" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Eosinophilic pneumonias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687710" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Parasites of the air passages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28225641" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A Review of Clinical and Imaging Findings in Eosinophilic Lung Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7952571" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Eosinophilic lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8872069" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pulmonary eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1520060" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reevaluation of eosinophilic pneumonia and its diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285120" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181338" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A clinical study of idiopathic eosinophilic pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6628020" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Eosinophilic pneumonia without radiographic pulmonary infiltrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6628020" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Eosinophilic pneumonia without radiographic pulmonary infiltrates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13331628" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Transient lung infiltrations with blood eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21186197" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Thoracic imaging findings in a case of disseminated cysticercosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1623771" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute eosinophilic pneumonia due to toxocariasis with bronchoalveolar lavage findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12135183" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic eosinophilic pneumonia due to visceral larva migrans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11137487" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pulmonary manifestations of early schistosome infection among nonimmune travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486834" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Tropical pulmonary eosinophilia: a case series in a setting of nonendemicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1580599" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tropical pulmonary eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24135173" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tropical pulmonary eosinophilia--a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838885" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Tropical pulmonary eosinophilia: a comparative evaluation of plain chest radiography and computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8560543" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Syndrome resembling tropical pulmonary eosinophilia but of non-filarial aetiology: serological findings with filarial antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10959663" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Coccidioidomycosis as imported atypical pneumonia in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17108067" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3568777" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pulmonary eosinophilia in coccidioidal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29021482" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Disseminated Cryptococcosis with Marked Eosinophilia in a Postpartum Woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18709538" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Disseminated cryptococcal infection with eosinophilia in a healthy person.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21123163" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pulmonary cryptococcosis with severe eosinophilia in an immunocompetent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28454572" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1600796" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pulmonary eosinophilia in pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33446345" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acute Eosinophilic Pneumonia Associated With SARS-CoV-2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33235798" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute eosinophilic pneumonia accompanied with COVID-19: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31662996" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29369189" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Drug-induced eosinophilic pneumonia: A review of 196 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29369189" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Drug-induced eosinophilic pneumonia: A review of 196 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8162761" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Eosinophilic lung reaction to aluminium and hard metal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7662104" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [Occupational eosinophilic lung in a grape grower: role of sulfites].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2920603" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pulmonary infiltration with blood eosinophilia after scorpion sting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181370" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Löffler's syndrome secondary to crack cocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335147" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Eosinophilia, respiratory symptoms and pulmonary infiltrates in rubber workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12231487" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10830182" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute eosinophilic pneumonia associated with smoke from fireworks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10674853" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Acute eosinophilic pneumonia caused by cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8214799" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Acute eosinophilic pneumonia following intentional inhalation of Scotchguard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21547500" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lung immunoreactivity and airway inflammation: their assessment after scorpion envenomation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18365158" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Eosinophilic pneumonia associated with heroin inhalation: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23609259" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A novel cause of eosinophilic pneumonia: recreational marijuana exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613668" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8412642" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2398610" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Eosinophilia-myalgia syndrome. Results of national surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33957099" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : CT Findings and Patterns of e-Cigarette or Vaping Product Use-Associated Lung Injury: A Multicenter Cohort of 160 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9772920" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14738224" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chronic eosinophilic pneumonia after radiation therapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026185" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chronic eosinophilic pneumonia in a breast cancer patient post-radiation therapy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11243986" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chronic eosinophilic pneumonia presenting with recurrent massive bilateral pleural effusion : case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9730804" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chronic eosinophilic pneumonia with atypical radiographic presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23155215" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Tracheobronchial involvement in chronic eosinophilic pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9990352" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496231" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16612769" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Allergic bronchopulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30832470" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Allergic Bronchopulmonary Mycosis due to fungi other than Aspergillus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23383677" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943916" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : High-resolution computed tomography and pathologic findings in pulmonary aspergillosis: a pictorial essay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1092235" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bronchocentric granulomatosis, mucoid impaction, and hypersensitivity reactions to fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180373" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The idiopathic hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910029" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29803709" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hypereosinophilic syndrome in the differential diagnosis of pulmonary infiltrates with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2389917" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11144923" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Eosinophilic pneumonia-like areas in idiopathic usual interstitial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364784" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Eosinophilic pneumonia as an initial manifestation of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11404176" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Eosinophilic infiltrates in a pulmonary allograft: a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8684158" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : An emaciated man with eosinophilic pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342744" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hematologic Malignancies Identified in Patients with Hypereosinophilia and Hypereosinophilic Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33002503" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Approach to Eosinophilia Presenting With Pulmonary Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10966710" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Eosinophilic lung diseases: diagnostic accuracy of thin-section CT in 111 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2773727" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Chronic eosinophilic pneumonia: CT findings in six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8089322" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Chronic eosinophilic pneumonia: evolution of chest radiograms and CT features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15818205" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Churg-Strauss syndrome: high resolution CT and pathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11813820" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : High-resolution CT of drug-induced lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15932372" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Eosinophilic pneumonias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32052155" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30201098" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33636343" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33689868" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Real-World Effectiveness of Anti-IL-5/5R Therapy in Severe Atopic Eosinophilic Asthma with Fungal Sensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12403693" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Idiopathic acute eosinophilic pneumonia: a study of 22 patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
